PanDox: Targeted Doxorubicin in Pancreatic Tumours

Inclusion Criteria: * Able to give informed consent prior to any screening procedures being performed and is able and willing to comply with the protocol and its requirements. * Male or Female, aged 18 years or above. * Prior histological confirmation of pancreatic adenocarcinoma * Non-resectable or metastatic (stage IV) * The primary pancreatic lesion measuring at least 1.5cm minimum diameter and amenable to EUS biopsy sampling * ECOG performance status 0-1 (Appendix 1) * Left ventricular ejection fraction (LVEF) ≥ 50% as determined by echocardiogram * Willing to allow his or her General Practitioner and Consultant, if appropriate, to be notified of participation in the trial. * Life expectancy of at least 3 months * Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use highly effective contraception during the trial and for 6 months thereafter. * Participant has clinically acceptable laboratory results during screening window: Lab Test Value required Haemoglobin (Hb) (transfusion to achieve this allowed) ≥ 9g/dL Neutrophils ≥ 1.5 109/L Platelet count ≥ 100 109/L ALT ≤ 2.5 x ULN Alkaline phosphatase ≤ 5 x ULN Serum Bilirubin (stenting to achieve this allowed) ≤ 1.5 x ULN Creatinine Clearance (Calculated by Cockcroft-Gault criteria) ≥ 50ml/min INR \<1.5 unless taking oral anticoagulant (this to be stopped at least 1 week prior to biopsy, at which point th…